Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Severe Asthma Treatment, Bronchial Thermoplasty, Uses Radiofrequency Energy To Improve Patient Quality Of Life
Chronic asthma sufferers may find new relief in a simple, minimally invasive outpatient procedure known as bronchial thermoplasty, which uses controlled radiofrequency-generated heat to treat the muscles of the airways, preventing them from constricting and narrowing. The study, which was approved by the Food and Drug Administration (FDA), marks the most recent phase of investigational trials of the Alair System, the device used in the bronchial thermoplasty procedure. If approved, it would become the first non-pharmaceutical therapy to effectively treat severe asthma.
generic viagra online
Cepheid Receives FDA Clearance For First On-Demand Molecular Diagnostic Test For Clostridium Difficile Infection
Cepheid (Nasdaq: CPHD) announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(R) C. difficile test, an on-demand molecular diagnostic test designed for 45-minute detection of the bacterium that causes Clostridium difficile infection (CDI). The Xpert C. difficile test is the first test for CDI to deliver both rapid turnaround and a high degree of accuracy.
News of the day
Structure Of Antibiotic Ramoplanin Reveals Promising Mechanism
With the "last resort" antibiotic Vancomycin now plagued by the first signs of bacterial resistance, a scientific collaboration centered at Duke University has identified how a candidate successor antibiotic known as Ramoplanin A2 can kill pathogenic bacteria by interrupting how they form their cell membranes.
Cardiovascular

Combination Clomiphene Citrate And Antioxidant Therapy For Idiopathic Male Infertility: A Randomized Controlled Trial

UroToday.com - Empirical medical treatment for idiopathic male factor infertility is a controversial issue. Several medications are used empirically for the treatment of idiopathic male factor infertility, including follicle stimulating hormone (FSH), antiestrogen, L-carnitine, and antioxidants. In this study, we attempted to evaluate the effectiveness of the combination of clomiphene citrate and vitamin E in the management of men with idiopathic infertility. The study was designed as a prospective, randomized, placebo-controlled trial. The setting was the outpatient Andrology clinic, in Cairo University Hospitals. The study included sixty infertile men with idiopathic oligoasthenozoospermia. Patients were randomly assigned to two treatment groups: a group receiving the combination of clomiphene citrate (25 mg/day) and vitamin E (400 mg/day; n = 30) against a placebo group (n = 30). Treatment was continued for 6 months. The main outcome measures were the pregnancy rate and variations in semen parameters. The study followed an intention-to-treat analysis. A significantly higher pregnancy rate was found among the combination treatment group in comparison to the control group. The odds ratio was 3.76 and the 95% confidence interval was 1.03-13.64, with a 36.7% pregnancy rate (11/30) in the combination treatment group compared with 13.3% pregnancy rate (4/30) in the control group. The trial showed a significantly higher increase in sperm count and progressive sperm motility with insignificant changes in total sperm motility, percentage of abnormal forms and semen volume in the combination treatment group as compared to the control group. We conclude that the combination of clomiphene citrate as an antiestrogen and vitamin E as an antioxidant can significantly increase the pregnancy rate and improve sperm count and progressive sperm motility in cases of idiopathic oligoasthenozoospermia, with normal testicular size, normal or low normal FSH, and no known male or female factors. The treatment protocol is inexpensive, safe and easy to administer. Written by Hussein Ghanem, MD, Osama Shaeer, MD, and Amgad El-Segini, MD as part of Beyond the Abstract on UroToday.com. UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009